Tumour Ablation Devices Market Size, Share and Global Trend By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, High-Intensity Focused Ultrasound Ablation), By Treatment Type (Surgical, Laparoscopic, Percutaneous), By Application (Liver Cancer, Breast Cancer, Renal Cancer, Lung Cancer, Prostate Cancer), By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers) and Regional Forecast, 2024-2032

The increasing prevalence of cancer has surged the demand for effective minimally invasive treatment techniques, which targets only the tumor cells. Tumour ablation is a type of minimally invasive technique that is used to treat cancer. In tumor ablation, a probe is inserted into a minimal invasive hole which is capable of emitting high-frequency waves, and are used to kill the cancer tumors.

In some of the cancer treatments, tumours are killed with the help of extreme cold. The main advantage of tumor ablation devices is, it avoids open surgery, thus significantly reducing the pain and hospital stays. Certain cancer tumors such as prostate, liver, renal, thyroid, brain, lung, bone, and others can be treated with the help of tumor ablation devices.

To gain extensive insights into the market, Request for Customization

Rising prevalence of cancer, adoption of sedentary lifestyles, and the gradual shift towards minimally invasive surgical procedures are prominently driving the growth of the global tumor ablation devices market. Combined with this, certain advantages offered by tumor ablation devices such as minimal incision, less pain and & reduction in blood loss, shorter hospital stays, and rapid recovery are expected to boost the demand for tumor ablation devices during the forecast period.

However, lower accessibility to emerging nations, costly and complex installation, and lack of robust healthcare infrastructure in emerging nations are restraining the growth of the global tumor ablation devices market.

Key Players Covered

Some of the major companies that are present in the global tumor ablation devices market are Ethicon US, LLC., EDAP-TMS, Sonacare Medical, Medtronic, Boston Scientific Corporation, AngioDynamics, HealthTronics, Inc., Misonix, Galil Medical Inc., Baylis Medical Company, Inc., Koninklijke Philips N.V., and others.

SEGMENTATION

Based on technology, the radiofrequency ablation segment is anticipated to have a major portion of the global tumor ablation devices market owing to its preference over cryoablation technology. According to results of clinical research published in 2017, radiofrequency (RF) ablation therapies increase the chances of cancer curing by an estimated 40.0%, and additionally, an estimated 60.0% of cancer patients undergo radiotherapy across the globe, which is expected to fuel the radiofrequency ablation segment in the global tumor ablation devices during the forecast period.

Key Insights

• Prevalence of cancer for key countries


• Pricing analysis


• PEST analysis


• The regulatory scenario for key countries


• Reimbursement Scenario for key countries


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is projected to dominate the global tumor ablation devices market over the forecast period owing to the rising prevalence of cancer. According to the National Cancer Institute, 1.7 million new cases of cancer are estimated to be reported in the U.S. in 2018, which is expected to boost the demand for tumor ablation devices in North America. Combined with this, growing geriatric population, increasing adoption of advanced technology, and growing healthcare infrastructure is expected to play a pivotal role in increasing the demand for tumor ablation market in North America. Asia Pacific and Middle East & Africa also hold potential for adoption of tumor ablation devices owing to the rise in the prevalence of cancer and growth in prevalence of neoplastic diseases. According to the World Health Organization, in 2016, approximately 30 countries in Africa and Asia Pacific region had a shortfall of tumor ablation devices, which indicates a huge opportunity for tumor ablation devices in these regions.

Key Industry Developments

• In March 2019, Johnson & Johnson Services, Inc. announced the launch of global registry for the collection and analysis of data on patients having soft tissue liver lesions and treated with NEUWAVE Microwave Ablation System, the company’s microwave ablation device.
• In February 2019, J&J’s Biosense Webster initiated the trail for its IDE- Cleared Qdot Micro radiofrequency ablation system in order to treat symptomatic drug-refractory paroxysmal atrial fibrillation.
• In February 2019, Medtronic launched its new radiofrequency ablation system, Accurian, which is enabled with software for temperature control to offer high standard ablation procedure.
• In January 2019, Venclose, Inc., and Viant agreed upon a strategic partnership to design and develop Venclose’s next-generation VENCLOSE RF Ablation Catheter System.